{
    "nctId": "NCT02035800",
    "officialTitle": "Bone Resorption, Osteoclastogenesis and Adalimumab",
    "inclusionCriteria": "* Patients aged of 18 and over,\n* Satisfying the 1987 American College of Rheumatology (ACR) criteria for RA\n* Receiving a prescription of Adalimumab 40 mg subcutaneous every two weeks.\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Patients not capable or willing to provide informed consent\n* Patients starting Adalimumab less than five half-lives after the interruption of a previous anti-TNF therapy."
}